Last reviewed · How we verify
relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation
Approved treatments
- Revuforj · Syndax
Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells. - Komzifti · Kura
Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells. - Komzifti · Kura
Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation patent landscape — cliff calendar, originator estates, attackable patents
- relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation treatment landscape brief
- relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation treatment updates RSS
Frequently asked questions about relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation
What drugs treat relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation?
Tracked treatments include Revuforj, Komzifti.
What is the treatment for relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation?
Standard treatment for relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation includes Revuforj, Komzifti. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation patent cliff · relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation CI report
- Treatment: Revuforj · Syndax
- Treatment: Komzifti · Kura
- Treatment: Komzifti · Kura
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing